Evidence map›Paper›PMID 34456719›Full record

ArticleFrontiers in pharmacology2021

Beneficial Treatment Outcomes of Severe COVID-19 Patients Treated Entirely in Primary Care Settings With Dexamethasone Including Regimen-Case Series Report.

Damir Vukoja, Andrea Jurić, Zdravka Erkapić, Tomislav Pejić, Željko Zovko, Josipa Juričić, Jelena Pejić, Matea Ćorluka

Abstract readCase Reports
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Damir VukojaGrude Health Center, Grude, Bosnia and Herzegovina.
Andrea JurićInstitute for Public Health of West Herzegovina County, Grude, Bosnia and Herzegovina.
Zdravka ErkapićGrude Health Center, Grude, Bosnia and Herzegovina.
Tomislav PejićGrude Health Center, Grude, Bosnia and Herzegovina.
Željko ZovkoGrude Health Center, Grude, Bosnia and Herzegovina.
Josipa JuričićGrude Health Center, Grude, Bosnia and Herzegovina.
Jelena PejićDepartment of Dermatology and Venerology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Matea ĆorlukaDepartment of Dermatology and Venerology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Even in 2021, coronavirus disease 2019 (COVID-19) remains a major global health concern, especially in developing countries. The burden of this disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which affects not only primary respiratory but also other organ systems, keeps rising as the pandemic continues. Primary health care centers are the first line where COVID-19 patients are managed and should be able to manage the vast majority of them successfully. In this paper, we present a case series and concept of beneficial management of even deteriorating and severe patients treated entirely in our primary health center. The management is based on well-timed and rational dexamethasone use, as well as on various other pharmacological and nonpharmacological treatments and interventions, and is supported by provided statistical data. According to the presented experience and positive outcomes achieved, it seems that even deteriorating and severe COVID-19 patients can be treated successfully to some extent or even completely in primary care settings. This kind of approach could be particularly beneficial in conditions of overload of higher-level health care institutions.

Indexed as

coronaviruscorticosteroidsCOVID-19dexamethasoneprimary health careSARS-CoV-2treatment

Identifiers

PMID34456719
PMCPMC8387596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.